Understand the source comparison
Peptides for Keloid Treatment Protocol Evidence Guide: Dosing and Administration Comparison
BPC-157 TGF-β1 reduction, collagen III upregulation, angiogenesis 250–500 mcg per site every 48–72 hours for 6 weeks Subcutaneous injection adjacent to wound or scar Preclinical (in vitro keloid fibroblast studies show TGF-β suppression) No completed keloid-sp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- TGF-β1 reduction, collagen III upregulation, angiogenesis
- 250–500 mcg per site every 48–72 hours for 6 weeks
- Subcutaneous injection adjacent to wound or scar
- Preclinical (in vitro keloid fibroblast studies show TGF-β suppression)
- No completed keloid-specific RCTs
- TB-500
- MMP-2/9 upregulation, collagen degradation, fibroblast contractility reduction
- 5 mg subcutaneously twice weekly for 6–8 weeks
- Subcutaneous or intralesional injection
- Case series in hypertrophic scar prevention; mechanistic rationale strong
- Phase I safety data in wound healing; no keloid trials
- GHK-Cu
- Decorin expression, TGF-β1 sequestration, MMP-1 upregulation, ROS scavenging
- 2–5 mg per site weekly for 6–12 weeks, or 0.5–2% topical twice daily
- Intralesional injection or topical application
- In vitro keloid fibroblast studies; dermatology case reports for scar remodeling
- Phase II cosmetic trials; keloid data limited to observational reports